Urine Drug Testing

Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary.

42 CFR 410.32(a) indicates that diagnostic tests may be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements). 

42 CFR 411.15(k)(1) indicates coverage exclusion for any services that are not reasonable and necessary for the following purpose: For the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

CMS Internet Only Manual, Pub 100-02 Medicare Beneficiary Policy Manual Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests, §80.1.1 Certification Changes.

Purpose

Urine drug testing (UDT) provides timely, objective, and actionable information to clinicians by identifying the presence or absence of drugs of potential abuse in the body to assist the clinician in making treatment decisions.¹

This policy details:

• The appropriate indications and allowed number of UDTs billed over time for safe medication management of prescribed substances in risk stratified pain management patients and/or in identifying and treating substance use disorders (SUDs);
• Designates documentation, by the clinician caring for the beneficiary in the beneficiary’s medical record, of medical necessity for, and testing ordered on an individual patient basis;
• Provides an overview of presumptive UDT and definitive UDT testing by various methodologies.

This policy addresses UDT for Medicare patients only.

Definitions

As used in this document, the following terminology relates to the basic forms of UDT:

1. Presumptive/Qualitative Drug Testing (hereafter called "presumptive" UDT) – Covered when medically necessary to immediately determine the presence or absence of drugs or drug classes in a urine sample. Presumptive UDT results are expressed as negative or positive or as a numerical result; includes competitive immunoassays (IA) and thin layer chromatography.²
2. Definitive/Quantitative/Confirmation Testing (hereafter called “definitive” UDT) – Covered when clinically indicated and medically reasonable and necessary based on this Local Coverage Determination (LCD) to identify specific medications, illicit substances and metabolites. Definitive UDT reports the results of analytes absent or present typically in concentrations such as ng/mL; definitive methods include but are not limited to Gas Chromatography coupled with Mass Spectrometry (GC-MS) and Liquid Chromatography coupled with Mass Spectrometry (LC-MS/MS) testing methods.²
3. Specimen Validity Testing - Urine specimen testing to ensure that it is consistent with normal human urine and has not been adulterated or substituted, may include, but is not limited to pH, specific gravity, oxidants and creatinine. This however is quality assurance, not a Medicare benefit, and thus not separately payable by Medicare.
4. Immunoassay (IA) - Ordered by clinicians primarily to identify the presence or absence of drug classes and some specific drugs; biochemical tests that measure the presence above a cutoff level of a substance (drug) with the use of an antibody; read by photometric technology.²
5. Point of Care Testing (POCT) – Covered when medically necessary by clinicians caring for the beneficiary for immediate test results for the immediate management of the beneficiary; available when the beneficiary and physician are in the same location; IA test method that primarily identifies drug classes and a few specific drugs; platform consists of cups, dipsticks, cassettes, or strips; read by the human eye, or read by instrument assisted direct optical observation.³
6. Standing Orders - Test request for a specific patient representing repetitive testing to monitor a condition or disease for a limited number of sequential visits; individualized orders for certain patients for pre-determined tests based on historical use, risk, and community trend patient profiles; clinician can alter the standing order. *Note: A profile is developed based on specific characteristics of a specific patient, while a panel is a general non-specific group of tests that may have unnecessary tests for the specific patient being treated.
7. Blanket Orders - Test request that is not for a specific patient; rather, it is an identical order for all patients in a clinician’s practice without individualized decision making at every visit.
8. Reflex Testing - Laboratory testing that is performed "reflexively" after initial test results to identify further diagnostic information essential to patient care. This testing is not necessarily based on a specific physician's order. 

Drug Testing Methods

The Clinical Laboratory Improvement Amendments (CLIA) regulates laboratory testing and requires clinical labs to be certified by their state as well as the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.³ Multiple types of CLIA certificates may be obtained based on the complexity of testing a lab conducts. CLIA levels of complexity (CLIA-waived, moderate complexity and high complexity) are addressed only as they correspond to the Healthcare Common Procedure Coding System (HCPCS) code description in the related billing and coding article.

A. Presumptive Testing Methods:

1. Presumptive UDT:

A presumptive UDT consists of various platforms including cards, dipsticks, cassettes and cups based on qualitative competitive IA methodology with 1 or more analytes in the test. A presumptive IA test detects the presence of the amount of drug/substance present in urine above a predetermined “cut-off” value and may be read by direct optical observation or by instrument assisted direct optical observation.

A positive test result is reported when the concentration of drug is above the cutoff; a negative is reported when the concentration of drug is below the cut-off. Positive test results are presumptive but not necessarily definitive due to sensitivity and cross-reactivity limitations.⁴ Negative test results do not necessarily indicate the absence of a drug or substance in the urine specimen.³ The accuracy of the results of a presumptive UDT will depend on the testing environment, type of test, the drug being tested for and training of the individual conducting the test.

This type of test should only be used when results are needed immediately.

2. Presumptive UDT by Instrumented Chemistry Analyzers:

Chemistry analyzers with IA UDT technology can be used in an office or clinical laboratory setting. This test provides less immediate test results. At no time is IA technology by chemistry analyzer analysis considered confirmatory (definitive) testing.

A presumptive positive IA test detects the presence of a drug/substance in urine at or above the “cut-off” value. If the concentration of the drug is below the cut-off, the result will be negative. Presumptive positive tests are not always true positives due to sensitivity, specificity, and cross-reactivity limitations. Negative test results do not necessarily indicate the absence of a drug or substance in the urine specimen.³

Food and Drug Administration (FDA) approved/cleared test platforms are available in the marketplace, as well as laboratory developed tests (LDTs) such as modified FDA approved/cleared and non-FDA approved/cleared platforms and/or reagents. LDTs generally have been modified to test at a lower cut-off in order to detect substances that would have been missed at a higher cut-off. For example, an FDA labeled cut-off may be 300 ng/mL and the LDT cut-off for the same drug may be 100 ng/mL.³

Presumptive UDT can be carried out at any validated cut-off concentration. Lowering of the cut-off concentration provides more stringent cutoffs for illicit drugs. LDTs may include non-FDA cleared tests not available in CLIA-waived or moderate complexity tests (e.g., tramadol, tapentadol, carisoprodol, fentanyl, zolpidem). Lowering the cutoff increases the possibility of detecting a drug when the test has been modified from the recipe of the manufacturer.

3. Limitations of Presumptive UDT:

Presumptive UDT testing is limited due to:

• • Primarily screens for drug classes rather than specific drugs, and therefore, the practitioner may not be able to determine if a different drug within the same class is causing the positive result;
  • Produces erroneous results due to cross-reactivity with other compounds or does not detect all drugs within a drug class;⁵
  • Given that not all prescription medications or synthetic/analog drugs are detectable and/or have assays available, it is unclear as to whether other drugs are present when some tests are reported as positive;
  • Cut-off may be too high to detect presence of a drug.⁵

These limitations may mean that presumptive testing is insufficient for certain clinical needs.

An IA involves an antibody that reacts best with the stimulating drug and reacts to a lesser extent (cross-reactive) or not at all with other drugs in the drug class. While presumptive tests vary in their ability to detect illicit drugs such as tetrahydrocannabinol (THC), cocaine, 3,4-methylenedioxy-N- methylamphetamine (MDMA; “ecstasy”), and phencyclidine (PCP), they may not be optimal tests for many prescription drugs, such as: opiates, barbiturates, benzodiazepines and opioids.

For example, opiate reagents are formulated from morphine. Consequently, the cross-reactivity for other opioids and opiates varies based on the manufacturer and lot number. The semisynthetic opioids, hydromorphone and hydrocodone, may contribute to a positive presumptive result, while the semisynthetic opioids, oxycodone and oxymorphone, will not typically be detected even at a 300 ng/mL cutoff. Synthetic opioids, such as fentanyl, meperidine and methadone, will not be detected by current opiate IA testing. Consequently, a positive opiate result by IA normally necessitates more specific identification of the substance(s) that account for the positive result, and a negative result does not rule out the presence of opiates or opioids.⁶

Presumptive UDT reagents for benzodiazepine are typically formulated for oxazepam, a metabolite of diazepam (Valium^®) and chlordiazepoxide (Librium^®), the main benzodiazepines prescribed 20 years ago. However, many of the more than 10 benzodiazepines that are currently available do not cross-react with IA benzodiazepine reagents. In particular, clonazepam and lorazepam give false negative results with presumptive IA tests and may necessitate more specific identification to account for the negative result. Similarly, a positive screening test result may require definitive UDT to identify the specific drug(s).

Synthetic/analog or “designer” drugs manufactured to elude law enforcement require definitive testing for detection. Most commercially available IA reagents fail to detect designer drugs, such as psychedelic phenethylamines even at very high concentrations.

In summary, presumptive IA UDT is often unable to identify specific drugs within many drug classes, particularly within the amphetamine, barbiturate, benzodiazepine, tricyclic antidepressants, and opiate/opioid drug classes. Drugs such as buprenorphine, amphetamines, benzodiazepines, and cocaine/heroin yield false negative IA results due to low cross-reactivity or non-reactivity. Drugs such as fentanyl, carisoprodol, tramadol, tapentadol and synthetic designer drugs cannot be detected by presumptive IA; therefore, it may be medically necessary for clinicians to utilize definitive UDT when the presumptive tests for these drugs are negative.^1,5

B. Definitive UDT:

GC-MS and LC-MS/MS are complex technologies that use the separation capabilities of gaseous or liquid chromatography with the analytical capabilities of mass spectrometry. These methodologies require the competency of on-site highly trained experts in this technology and interpretation of results. While these tests require different sample preparation and analytical runs, they identify specific drugs, metabolites, and most illicit substances and report the results as absent or present typically in concentrations of ng/mL.²

Quantification should not be used to determine adherence with a specific dosage or time of dose of a pain medication or illicit drug for clinical purposes. Rather, the use of quantitative drug data may be important for many reasons such as in a differential patient assessment.¹ For example, when several opioids are present in the urine of a patient prescribed a single opioid, quantification may help the clinician decide whether the presence of the other opioids is consistent with metabolism of the prescribed opioid, opioid contamination during manufacturing, or if more than 1 drug within a class is being used.

Quantification may also provide information in the setting of illicit drug use. Serial creatinine-corrected quantitative values may assist in the differential assessment of ongoing drug use or cessation of drug use with continued drug excretion.¹

1. GC-MS

GC-MS can only be performed on molecules that are volatile. If the test drug is not volatile in its own right, it must be modified or derivatized to a volatile form. To derivatize, the test drug must be extracted from the urine, eluted from the extraction device, concentrated, and then reacted with a chemical reagent to make a volatile product. Each drug class may require a different derivatizing agent. For patients on multiple classes of medications, laboratories using GC procedures must make different volatile derivatives in order to perform comprehensive testing. Since a GC column may not be able to separate more than 1 class of compounds, multiple chromatographic runs on different column types may be required to monitor multiple drug classes.¹ Newer GC-MS instruments often use tandem systems. GC-MS methodology allows for the testing of multiple substances but differs in ease of run.

2. LC-MS/MS

LC-MS/MS is roughly 100 times more sensitive and selective, involves fewer human steps, provides quicker turn-around time, uses less specimen volume and can test for a larger number of substances simultaneously when compared to GC-MS.¹ After sample preparation, it is injected into the LC-MS/MS. The sample has to undergo hydrolysis to break the glucuronide bond that frees the drug and drug metabolites. Hydrolysis is followed by multiple additional steps including protein precipitation, centrifugation and purification. Deuterium-labeled isotopic internal standards are added to quantify the drugs and drug metabolites.

The sample is injected when the mobile phase is flowing through the chromatographic column. Each drug and drug metabolite interacts with the mobile phase and stationary phase differently and moves at different speeds depending on their chemical properties. In other words, each analyte elutes at different times. Specific drugs and metabolites are identified by their retention time and quantified against isotopic internal standards for each drug and metabolite. Each drug peak has a minimum of 2 mass transmissions to be compared to drug standards (calibrators) to ensure identification.

CLIA-Certified Laboratories-Informational Only

CLIA specifies quality standards for proficiency testing, facility administration, general laboratory systems, pre-analytic, analytic and post-analytic systems, onsite supervision requirements, personnel qualifications and responsibilities, quality control, and quality assessment.³

High complexity laboratories must ensure that testing is carried out by onsite qualified, trained personnel using validated reliable methods compliant with regulatory procedures (42 CFR Part 493). Both GC-MS and LC-MS/MS require a quality program to monitor the quality and audit the competency of the staff. LC-MS/MS instrument maintenance must be performed daily as well as the validation of instrument performance prior to patient specimens. Final review and approval of GC-MS and LC-MS/MS results must be performed by a qualified clinical laboratory scientist as defined in 42 CFR Part 493.1489 (Testing Personnel Qualifications). A GC-MS or LC-MS/MS laboratory must have a qualified laboratory director, qualified physician, or qualified clinical laboratory scientist, as provided in 42 CFR 493.1443 (Laboratory Director Qualifications).

Purpose of UDT:

Presumptive UDT may be ordered by the clinician caring for a beneficiary when it is necessary to rapidly obtain and/or integrate results into clinical assessment and treatment decisions.

Definitive UDT is considered reasonable and necessary when the clinical information supplied supports the definitive testing as in:

• Identifies a specific substance or metabolite that is inadequately detected by a presumptive UDT screen;
• Definitively identifies specific drugs in a large family of drugs;
• Identifies a specific substance or metabolite that is not detected by presumptive UDT such as fentanyl, meperidine, synthetic cannabinoids and other synthetic/analog drugs;
• Identifies drugs when a definitive concentration of a drug is needed to guide management (e.g., discontinuation of THC use according to a treatment plan);
• Identifies a negative or confirms a positive presumptive UDT result that is inconsistent with a patient’s self-report, presentation, medical history, or current prescribed pain medication plan;
• Rules out an error as the cause of a presumptive UDT result;
• Identifies non-prescribed medication or illicit use for ongoing safe prescribing of controlled substances; and
• For use in a differential assessment of medication efficacy, side effects, or drug-drug interactions.

Definitive UDT may be reasonable and necessary based on patient specific indications, including historical use, medication response, and clinical assessment, when accurate results are necessary to make clinical decisions.¹ To establish that a test is reasonable and necessary, the clinician’s rationale for the definitive UDT and the tests ordered must be documented in the patient’s medical record.

Drug Testing Panels

1. Presumptive UDT Panels

   Presumptive UDT typically involves testing for multiple analytes based on the specific beneficiary's clinical history and risk assessment. This information must be documented in the medical record. Presumptive UDT may be ordered as a panel and billed as a “Per Patient encounter” regardless of the number of analytes tested.

2.  Definitive UDT Panels

Physician-directed definitive profile testing is reasonable and necessary when ordered for a particular patient based upon historical use, clinical findings and community trends. However, the same physician-defined profile is not reasonable and necessary for every patient in a physician’s practice. Definitive UDT orders should be individualized, based on clinical history and risk assessment. This information must be documented in the medical record.

Specimen Type

Urine or oral fluid is the preferred biologic specimen for testing because of the ease of collection, storage, and cost-effectiveness.¹ UDT cannot detect the dosage of drug ingested/used, the time of use, or the means of delivery (intravenous vs. oral vs. inhaled). Detection time of a substance in urine is typically 1-3 days depending on the drug, rate of metabolism, and rate of excretion. Lipid-soluble drugs, such as marijuana, may remain in body fat and be detected upwards of a week or more.

Ethanol is not discussed in this LCD.

Ethanol is a known drug of abuse but is routinely tested in blood, not urine. In addition, the Drug Enforcement Administration (DEA) Resource Guide⁷ states that alcohol is exempt from control by the Controlled Substances Act (CSA). 

Covered Indications for UDT

Group A – Symptomatic patients, Multiple drug ingestion and/or Patients with unreliable history

A patient who presents in a variety of medical settings with signs or symptoms of substance use toxicity will be treated presumptively to stabilize the patient while awaiting presumptive, then definitive testing to determine the cause(s) of the presentation. The need for definitive UDT is based upon presumptive test findings, responses to medical interventions, and treatment plan.¹ A presumptive UDT should be performed as part of the evaluation and management of a patient who presents in an emergency room or urgent care setting with any 1 of the following:

• • Coma;
  • Altered mental status in the absence of a clinically defined toxic syndrome or toxidrome;
  • Severe or unexplained cardiovascular instability (cardiotoxicity);
  • Unexplained metabolic or respiratory acidosis in the absence of a clinically defined toxic syndrome or toxidrome;
  • Seizures with an undetermined history; or
  • To provide antagonist to specific drug(s).

The presumptive findings, definitive drug tests ordered, and reasons for the testing must be documented in the patient's medical record.

Group B - Diagnosis and treatment for substance abuse or dependence

A patient in active treatment for a SUD or monitoring across different phases of recovery may undergo medical management for a variety of medical conditions. A physician who is writing prescriptions for medications to treat either the SUD or other conditions may need to know if the patient is taking substances which can interact with prescribed medications or if the patient is taking prescribed medications as expected.¹ The risk of drug-drug interactions is inherent to the patient and may be compounded by prescribed medications. UDT is a medically necessary and useful component of chemical dependency diagnosis and treatment. The UDT result influences treatment and level of care decisions.³ Ordered tests and testing methods (presumptive and/or definitive) must match the stage of screening, treatment, or recovery; the documented history; and Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnosis. For patients with no known indicators of risk for SUDs, the clinician may screen for a broad range of commonly abused drugs using presumptive UDT. For patients with known indicators of risk for SUDs, the clinician may screen for a broad range of commonly abused drugs using definitive UDT. For patients with a diagnosed SUD, the clinician should perform random UDT at random intervals to properly monitor the patient.³ Testing profiles must be determined by the clinician based on the following medical necessity guidance criteria:

• • Patient history, physical examination, and previous laboratory findings;
  • Stage of treatment or recovery;
  • Suspected abused substance;
  • Substances that may present high risk for additive or synergistic interactions with prescribed medication (e.g., benzodiazepines, alcohol).

The patient’s medical record must include an appropriate number of UDTs billed over time based on the stage of screening, treatment, or recovery;⁹ the rationale for the drugs/drug classes ordered; and the results must be documented in the medical record and used to direct care.³

1. Maximum Number of Allowed Presumptive UDTs for SUD

The number of UDTs billed over time must meet medical necessity and be documented in the patient’s medical record.⁸

1. 1. 1. For patients with 0 to 30 consecutive days of abstinence, presumptive UDT is not to exceed 3 presumptive UDTs in a rolling 7 days. More than 3 presumptive UDTs in a rolling 7 days is not reasonable and necessary and is not covered by Medicare.
      2. For patients with 31 to 90 consecutive days of abstinence, presumptive UDT is not to exceed 3 presumptive UDTs in a rolling 7 days. More than 3 presumptive UDTs in a rolling 7 days is not reasonable and necessary and is not covered by Medicare.
      3. For patients with > 90 consecutive days of abstinence, presumptive UDT is not to exceed 3 presumptive UDTs in a rolling 30 days. More than 3 presumptive UDTs in a rolling 30 days is not reasonable and necessary and is not covered by Medicare.

2. Maximum Number of Allowed Definitive UDTs for SUD

Depending on the patient’s specific substance use history, definitive UDT to accurately determine the specific drugs in the patient’s system may be necessary. Definitive testing may be ordered when accurate and reliable results are necessary to integrate treatment decisions and clinical assessment. The number of UDTs billed over time and the rationale for definitive UDT must be documented in the patient’s medical record.

1. 1. 1. For patients with 0 to 30 consecutive days of abstinence, definitive UDT is not to exceed 1 definitive UDT in a rolling 7 days. More than 1 definitive UDT in a rolling 7 days is not reasonable and necessary and is not covered by Medicare.
      2. For patients with 31 to 90 consecutive days of abstinence, definitive UDT is not to exceed 3 definitive UDTs in a rolling 30 days. More than 3 definitive UDTs in a rolling 30 days is not reasonable and necessary and is not covered by Medicare.
      3. For patients with > 90 days of consecutive abstinence, definitive UDT is not to exceed 3 definitive UDTs in a rolling 90 days. More than 3 definitive UDTs in a rolling 90 days is not reasonable and necessary and is not covered by Medicare.

Group C - Treatment for patients on chronic opioid therapy (COT)

A physician who is writing prescriptions for medications to treat chronic pain can manage a patient better if the physician knows whether the patient is consuming another medication or substance, which could suggest the possibility of SUD or lead to drug-drug interactions. Additionally, UDT may help the physician monitor for medication adherence, diversion, efficacy, side effects, and patient safety in general.¹⁰ A broad cross section of the general population will develop either cancer pain syndrome or non-cancer pain which will require prolonged or chronic opioid therapy for management with normal risk of addiction inherent to the substance(s) exposed.¹¹

Providers should consider the prescribed medications, risk assessment, and clinical presentation when selecting which tests to order.

There are multiple validated surveys the provider can use as part of routine assessment of the individual’s risk potential for abuse and diversion. These surveys typically ask the same questions that are part of the routine clinical assessment. This A/B MAC removed the validated survey requirement as this should already be part of the required clinical assessment.

Risk assessment is a widely accepted standard by expert treating entities to be used in clinical treatments and follow-up. The provider shall clearly define risk assessment as part of the reasonable and necessary criteria for UDT.

Other Contractor(s)' Policies

Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients of opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain. 2007;23(2):173-179.

Barthwell AG. Principles for urine drug testing in addiction medicine. CLAA.

Centers for Disease Control. Policy Impact: Prescription painkiller overdoses.

Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Assessment and management of chronic pain. November 2011.

Jackman RP, Purvis JM, Mallett BS. Chronic nonmalignant pain in primary care. Am Fam Physician. 2008;78(10):1155-1162.

Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. Pain. 2010;150(3):390-400.

Jones T, Moore T, Levy JL, et al. A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain. 2012;28(2):93-100.

University of Washington, Division of Pain Medicine, Urine Drug Testing (UDT) Interpretive Algorithm for Monitoring Opioid Treatment (adapted from the Washington State Agency Medical Directors Group Opioid Treatment Guidelines 2010).

Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician. 2008;11(2 Suppl):S5-S62.

Jones T, Moore T. Preliminary data on a new opioid risk assessment measure: the brief risk interview. Journal of Opioid Management. 2013;9(1):19-27.

Jones T, Passik SD. A comparison of methods of administering the opioid risk tool. Journal of Opioid Management. 2011;7(5):347-351.

Mallya A, Purnell AL, Svrakic DM, et al. Witnessed versus unwitnessed random urine tests in the treatment of opioid dependence. Am J Addict. 2013;22(2):175-177.

Moore TM, Jones T, Browder JH, Daffron S, Passik SD. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids of chronic pain management. Pain Medicine. 2009;10(8):1426-1433.

Nafziger AN, Bertino JS. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain. 2009;25(1)73-79.

Nicholson B, Passik SD. Management of chronic non-cancer pain in the primary care setting. SMJ. 2007;100(10):1028-1036.

Passik SD, Jones TW. Risk assessment 2.0. PWJ. 2013;1(3):5-9.

Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis uses in patients prescribed chronic opioid therapy: A review of the extant literature. Pain Med. 2009;10(8):1434-1441.

Schneider J, Miller A. Urine drug tests in a private chronic pain practice. PPM. 2008;8(1)62-66.

Department of Health and Human Services, Office of Inspector General. Opportunities exist for CMS and its Medicare contractors to strengthen program safeguards to prevent and detect improper payments for drug testing services. Accessed 06/14/2024.

1. DuPont RL, Shea CL, Barthwell AG, et al. Drug testing: A white paper of the American Society of Addiction Medicine (ASAM). American Society of Addiction Medicine. 2013:1-107.
2. Gourlay DL, Heit HA, Caplan YH. Urine drug testing in clinical practice. The art and science of patient care. 2015(6):1-30.
3. SAMHSA, Clinical drug testing in primary care, Rockville, MD: SAMHSA; 2012. Technical Assistance Publication (TAP) 32, HHS publication (SMA) 12-4668.
4. Agency Medical Directors Group (AMDG). Interagency guideline on opioid dosing for chronic non-cancer pain: An educational aid to improve care and safety with opioid therapy. 2010. Accessed 6/14/24.
5. Melanson SEF, Baskin L, Magnani B, Kwong TC, Dizon A, Wu AHB. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Arch Pathol Lab Med. 2010;134:735-739.
6. Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician. 2010;81(5):635-640.
7. Drug Enforcement Administration, U.S. Department of Justice, Drugs of Abuse: A DEA Resource Guide, 2020 Edition. Accessed 6/14/24.
8. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline—using clinical laboratory tests to monitor drug therapy in pain management patients. The Journal of Applied Laboratory Medicine. 2018;2(4):489–526.
9. AMA Report 2 of the Council on Science and Public Health (I-08): Improving medical practice and patient/family education to reverse the epidemic of nonmedical prescription drug use and addiction.
10. The American Academy of Pain Medicine. Use of opioids for the treatment of chronic pain, a statement from the American Academy of Pain Medicine.2013;1-4.
11. Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management: instruments for screening, treatment planning and monitoring compliance. Pain Med. 2008;9:S145-S166.
12. Jones T, McCoy JD, Moore T, Daffron S, Browder JH. Urine drug testing as an evaluation of risk management strategies. Practical Pain Management. 2010;10(5):26-30.
13. Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2):113-130.
14. Federation of State Medical Boards (FSMB), Guidelines for the Chronic Use of Opioid Analgesics. 2017.
15. Passik SD. Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84(7):593-601.
16. Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010.
17. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid risk tool. Pain Med. 2005;6(6):432-442.

• Urine Drug Testing
• UDT